U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C18H18F3NO4
Molecular Weight 369.335
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETOFENAMATE

SMILES

OCCOCCOC(=O)C1=CC=CC=C1NC2=CC(=CC=C2)C(F)(F)F

InChI

InChIKey=XILVEPYQJIOVNB-UHFFFAOYSA-N
InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2

HIDE SMILES / InChI

Description

Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Cyclooxygenase-1
131
Inhibitor
8,504
Cyclooxygenase-2
201
Inhibitor
8,504
lipoxygenase pathway
1
Inhibitor
8,504
 53.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Muscle pain
7
 Palliative
Approved
8,583
Etofenamate
Joint pain
1
 Palliative
Approved
8,583
Etofenamate

Cmax

ValueDoseCo-administeredAnalytePopulation
5810 ng/mL
1 g single, intramuscular
 FLUFENAMIC ACID plasma
Homo sapiens
31.3 ng/mL
230 mg single, topical
 FLUFENAMIC ACID plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
168100 ng × h/mL
1 g single, intramuscular
 FLUFENAMIC ACID plasma
Homo sapiens
449 ng × h/mL
230 mg single, topical
 FLUFENAMIC ACID plasma
Homo sapiens
484 ng × h/mL
230 mg 2 times / day multiple, topical
 FLUFENAMIC ACID plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
9.18 h
1 g single, intramuscular
 FLUFENAMIC ACID plasma
Homo sapiens

Doses

AEs

PubMed

Patents

JP2002528495A
37
JP2011524416A
146

Sample Use Guides

In Vivo Use Guide
Intramuscular Pain and inflammation Adult: 1 g injected deeply in single doses. Topical/Cutaneous Pain and inflammation Adult: Apply 5% or 10% conc topically on affected area.
Route of Administration: Other
In Vitro Use Guide
PGE2 generation by rat peritoneal macrophages in MEM medium was dose-relatedly inhibited with etofenamate at the dosage range of 1 to 30 uM.
ACTIVE MOIETY
Structure of ETOFENAMATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966